Support line (toll-free) (844) 835-4325 | Events help (608) 828-8852 | Community

Free To Breathe - A Partnership For Lung Cancer Survival

participant Login

News

Featured Clinical Trial of the Week: Improving Effectiveness of Chemotherapy

  • September 13 2013

    Share |
    Featured Clinical Trial of the Week: Improving Effectiveness of Chemotherapy

    Custirsen is a drug that may help improve lung cancer survival in an indirect way. Instead of working to directly kill tumor cells, custirsen makes the cells more vulnerable to chemotherapy. Researchers hope that, when used together, custirsen and chemotherapy will be more effective than chemotherapy alone. This clinical trial tests whether custirsen in combination with docetaxel, a standard chemotherapy drug, vs. docetaxel alone will be better at extending lung cancer patients’ lives.

    Eligibility
    Patients with advanced-stage non-small cell lung cancer that has recurred or progressed in spite of initial chemotherapy are eligible for this clinical trial.

    Visit ClinicalTrials.gov for more information on this trial.

    If you’re looking for further information on this and/or other lung cancer clinical trials, please contact our Clinical Trials Matching Service, where trained representatives will match your particular cancer and health issues to clinical trials that are available for you.

    0 comments

Leave a comment

Comment Guidelines

Basic HTML formatting permitted -
<ul>, <li>, <strong>, <em>, <a href>, <blockquote>, <code>

©2017 Free To Breathe | Lung Cancer Research Foundation | Federal Tax ID #14-1935776 | LCRF is a 501(c)(3) public charity.